A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 Mg Once Daily for 26 Weeks.

Trial Profile

A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 Mg Once Daily for 26 Weeks.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2009

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Gastrointestinal disorders; NSAID-induced gastric damage; NSAID-induced gastrointestinal damage; NSAID-induced ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTERIX
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Mar 2009 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
    • 11 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top